作者: Barbara Högy , Heinz-Otto Keinecke , Michael Borte
DOI: 10.1007/S10198-004-0250-5
关键词:
摘要: Primary antibody deficiencies are the most common forms of primary immunodeficiencies. Substitution therapy with polyvalent immunoglobulins has been established as standard for several decades. Until now mainly intravenous (IVIG) have used in Germany, and majority patients receive treatment hospital outpatient clinics. In recent years subcutaneous administration (SCIG) developed which is administered home self-infusion. Studies indicate no significant differences immunoglobulin substitution between SCIG IVIG concerning outcome. We carried out a cost-minimization analysis to compare two alternatives Germany. Under base case assumptions cost saving from perspective German statutory health insurance. The main drivers SCIG; incremental compared sensitive changes price body weight patient.